Foundayo vs Compounded Semaglutide: Why FDA-Approved Wins

This is the most important section on this page. The difference between an FDA-approved medication and a compounded version isn't just regulatory — it's about what's actually in the vial.

FDA-approved Foundayo:

• Manufactured under current Good Manufacturing Practice (cGMP) regulations
• Every batch tested for potency, purity, sterility, and stability
• FDA-inspected facilities with mandatory quality systems
• Consistent dose in every pill, every time

Compounded semaglutide:

• Not required to follow cGMP for most 503A pharmacies
• Independent testing has found 10–50% variability in actual semaglutide content
• Some vials contained less active ingredient than labeled — meaning you're underdosed
• Some contained more — meaning unexpected side effects or safety risks
• Contamination incidents have been reported, including bacterial contamination

The FDA has issued multiple warnings about compounded semaglutide products, including reports of adverse events linked to quality issues. Some compounding pharmacies have been cited for using semaglutide salt forms (like semaglutide sodium) that are not bioequivalent to the branded product.

Compounded semaglutide's main appeal was always price. But that advantage has shrunk dramatically:

• Compounded semaglutide: $129–200/mo (varies by pharmacy, dose, and includes consultation fees)
• Foundayo: $149/mo (starting dose) to $349/mo (max dose) via LillyDirect

At the starting dose, the difference is just $20–50/month. At higher doses, compounded semaglutide may save $100–150/mo — but you're trading FDA quality assurance, dose reliability, and legal certainty for that savings.

Hidden costs of compounded semaglutide:

• Telehealth consultation fees ($50–100+ per visit)
• Shipping costs
• Injection supplies (syringes, alcohol swabs, sharps container)
• No insurance eligibility — always cash pay
• No manufacturer savings cards

Foundayo with a savings card: $25/mo for eligible commercially insured patients. No compounded product can match that.

Compounded semaglutide existed in a legal gray area that is rapidly closing.

How compounding was allowed: Under the Federal Food, Drug, and Cosmetic Act (Section 503A/503B), pharmacies can compound medications when there is a documented shortage of the FDA-approved version. When Wegovy and Ozempic were in shortage (2022–2024), compounding semaglutide was legally defensible.

What changed:

• The FDA declared the semaglutide shortage resolved in early 2025
• Novo Nordisk (maker of Ozempic/Wegovy) has aggressively pursued legal action against compounders
• The FDA has sent warning letters and enforcement actions to multiple compounding pharmacies
• Several major telehealth platforms have stopped offering compounded semaglutide

The practical impact: Many patients on compounded semaglutide are finding their supply cut off with little notice. The number of pharmacies willing to compound semaglutide is shrinking rapidly. This creates a supply reliability risk that FDA-approved medications don't have.

Foundayo is fully legal, widely available, and not going anywhere. It's manufactured by Eli Lilly — one of the largest pharmaceutical companies in the world — with robust supply chain infrastructure.

Foundayo has its own clinical trial data. In the ATTAIN-1 Phase 3 trial, orforglipron at the max approved dose (17.2mg) produced 12.4% weight loss (completers) over 72 weeks. This is proven, reproducible, and published in peer-reviewed journals.

Compounded semaglutide has no clinical trial data of its own. Compounders rely on the efficacy data from Novo Nordisk's branded semaglutide trials (STEP, SUSTAIN, etc.). But that data applies to pharmaceutical-grade semaglutide manufactured under strict FDA oversight — not to compounded versions with variable potency.

The implication: If your compounded vial contains 30% less semaglutide than labeled (which independent testing has documented), you're not getting the results the clinical trials promised. You might be losing 10% body weight instead of 15% — and attributing the shortfall to your own diet or exercise, when the real problem is the drug.

With Foundayo, what's on the label is what's in the pill. Every time. That consistency is what clinical trial data is built on.

If you're currently on compounded semaglutide, here's how to transition:

1. Talk to your doctor about switching to Foundayo. You don't need to go through the telehealth platform that prescribed the compounded version.
2. Get a Foundayo prescription. Your doctor can prescribe it directly, or you can use LillyDirect's integrated telehealth service.
3. Start Foundayo at 0.8mg the day after your last compounded semaglutide injection. You'll titrate up every 30+ days.
4. Expect a transition period. Orforglipron is a different molecule than semaglutide. Your body will adjust to the new GLP-1 agonist over 2–4 weeks. Some patients notice slightly different side effect patterns.
5. Don't use both simultaneously. Do not take Foundayo while still injecting compounded semaglutide.

What to expect after switching:

• Consistent, reliable drug delivery every day
• No more injection supplies or sharps disposal
• Potential insurance coverage and savings card eligibility
• Peace of mind from an FDA-approved product